Conference Reports for NATAP

Back

4th Intl Lipodystrophy Workshop   San Diego at Coronado Beach, Sept 22-25, 2002     Lipodystrophy Workshop: Lipids and Cardiovascular Risk - Michael Dube, MD, Indiana University School of Medicine, ACTG researcher - (11/25/02)   4th Lipodystrophy Workshop: metabolic abnormalities, HCV/HIV coinfection, fat loss, HCV/HIV coinfection - Michael Dube, MD, Indiana University School of Medicine, ACTG researcher - (10/30/02)   Effect of d4T and AZT on Leg Fat Loss - (10/7/02)   Lipodystrophy, lactic acidosis/acidemia and mitochondrial toxicity issues - Written by Cecilia Shikuma, MD, University of Hawaii and ACTG lipodystrophy researcher - (10/7/02)   Effect of protease inhibitors on bone - Special report by Donald P. Kotler, MD, St Luke's-Roosevelt Medical Center, New York City - (9/26/02)   HCV Viral Load Increases on HAART But CD4 Increase from HAART is Not Blunted: implications for when to begin HIV & HCV therapy - (9/26/02)   HIV/Hepatitis & Insulin/Diabetes - (9/26/02)   Body Composition Changes Observed in ACTG 384 - (9/26/02)   Treating Diarrhea in HIV - (9/26/02)   36-week Safety and Tolerability Study of Extended-Release Niacin (ERN) for the Treatment of Elevated Triglycerides in HIV - (9/25/02)   Nukes, Fat Loss, Mitochondrial Toxicity, Lactate - discussed below - (9/25/02)   Switch Study From Nelfinavir to Atazanavir - (9/24/02)   HEPATITIS B PRIMER - (9/24/02)   Atazanavir: preliminary week 24 study results show no increase in glucose, cholesterol and triglycerides - (9/24/02)   LIPODYSTROPHY WORKSHOP day 1 - (9/23/02)